Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis

American Journal of Nephrology

Volumn 44, Issue 5, 2016, Pages 404-410

  Bushinsky, David A ^a   Rossignol, Patrick ^b   Spiegel, David M ^c   Benton, Wade W ^c   Yuan, Jinwei ^c   Block, Geoffrey A ^d   Wilcox, Christopher S ^e   Agarwal, Rajiv ^f  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Relypsa Inc   (United States)

^d Denver Nephrologists   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

End stage renal disease; Hemodialysis; Hyperkalemia; Patiromer; Phosphate; Potassium

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; COLESEVELAM; COLESTIPOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PATIROMER; PHOSPHATE; POTASSIUM; POLYMER;

ADULT; ANURIA; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FECES ANALYSIS; FECES LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOMAGNESEMIA; MALE; MEAL; MORNING DOSAGE; NORMAL VALUE; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIORITY JOURNAL; SIDE EFFECT; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED;

ADULT; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMERS; RENAL DIALYSIS;

EID: 84992709206     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000451067     Document Type: Article

References (22)

1. Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K: Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2: 999-1007.
2. Bushinsky D, Mayo M, Garza D, Stasiv Y, Wilson DJ, Du Mond C, Berman L, Epstein M: Wide range in variation in serum potassium in hyperkalemic patients with CKD; response to a fixed 60 mEq potassium diet. Abstract. J Am Soc Nephrol 2015; 26: 845A-846A.
3. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
4. Foley RN, Gilbertson DT, Murray T, Collins AJ: Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365: 1099-1107.
5. Veltassa (Patiromer) for Oral Suspension (Package Insert). Relypsa, Redwood City, 2015.
6. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators: Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372: 211-221.
7. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators: Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYSTDN randomized clinical trial. JAMA 2015; 314: 151-161.
8. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR: Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17: 1057-1065.
9. Agarwal R, Afzalpurkar R, Fordtran JS: Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994; 107: 548-571.
10. Li L, Harrison SD, Cope MJ, Park C, Lee L, Salaymeh F, Madsen D, Benton WW, Berman L, Buysse J: Mechanism of action and pharmacology of patiromer, a nonabsorbed crosslinked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 2016; 21: 456-465.
11. Wrong O, Metcalfe-Gibson A: The electrolyte content of faeces. Proc R Soc Med 1965; 58: 1007-1009.
12. Jadoul M, Thumma J, Fuller DS, Tentori F, Li Y, Morgenstern H, Mendelssohn D, Tomo T, Ethier J, Port F, Robinson BM: Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol 2012; 7: 765-774.
13. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP: Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int 2011; 79: 218-227.
14. Mc Causland FR, Waikar SS, Brunelli SM: Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int 2012; 82: 204-211.
15. Jadoul M, Karaboyas A, Goodkin DA, Tentori F, Li Y, Labriola L, Robinson BM: Potassium-binding resins: associations with serum chemistries and interdialytic weight gain in hemodialysis patients. Am J Nephrol 2014; 39: 252-259.
16. Hou S, McElroy PA, Nootens J, Beach M: Safety and efficacy of low-potassium dialysate. Am J Kidney Dis 1989; 13: 137-143.
17. Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B: Effect of patiromer on urinary ion excretion in healthy adults. Clin J Am Soc Nephrol 2016; 11: 1769-1776.
18. Bronner F, Pansu D: Nutritional aspects of calcium absorption. J Nutr 1999; 129: 9-12.
19. Flythe JE, Curhan GC, Brunelli SM: Disentangling the ultrafiltration rate-mortality association: the respective roles of session length and weight gain. Clin J Am Soc Nephrol 2013; 8: 1151-1161.
20. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC: Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 2009; 119: 671-679.
21. Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K: Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis 2015; 66: 1047-1055.
22. Spiegel DM: Magnesium in chronic kidney disease: unanswered questions. Blood Purif 2011; 31: 172-176.